Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications.
You successfully added item(s) to your cart
For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
ProSense® 750 EX is a protease activatable fluorescent in vivo imaging agent that is activated by key disease associated proteases such as Cathepsin B, L, S and Plasmin. ProSense750 EX is optically silent in its unactivated state and becomes highly fluorescent following protease-mediated activation.
ProSense750 EX can be used as a marker for disease progression and therapeutic response in animal models of arthritis. This agent can also be used as a marker for disease progression in animal tumor models.
|Fluorescent Agent Type||Activatable|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||ProSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||750 nm|
Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles associated with atherosclerotic disease, in vivo, would enable a robust additional understanding and analysis of disease progression and therapeutic response in research and drug development. We report the utility of the near infrared (NIR) protease-sensing, ProSense® 750 Fluorescent Pre-clinical Imaging Agent, in combination with the FMT® 2500 Quantitative Pre-clinical Imaging System for the non-invasive quantitative measurement of atherosclerotic disease biology and related response to therapy in apolipoprotein (apo) E-deficient mice in vivo. FMT (Fluorescence Molecular Tomography) imaging measured significant increases in aortic region protease activity with a range of values that were comparable to the range seen in the ex vivo aortic arches assessed by fluorescence reflectance imaging (FRI).
Epifluorescence (2D) imaging of superficially,implanted mouse tumor xenograft models offers,a fast and simple method for assessing tumor,progression or response to therapy. This approach,for tumor assessment requires the use of near,infrared (NIR) imaging agents specific for different,aspects of tumor biology, and this Application,Note highlights the ease and utility of multiplex,NIR fluorescence imaging to characterize the,complex biology within tumors growing in a living,mouse. IntegriSense™ 750 detects avb3 integrin,expression, BombesinRSense™ 680 detects the upregulation of bombesin receptor,(associated with tumor proliferation), Transferrin-Vivo™ 750 detects increases in,transferrin receptor (due to increased iron metabolism), MMPSense® 680 is activated,by disease-related matrix-metalloproteases (secreted by tumor cells and tumor,associated macrophages), and ProSense® 750EX detects increases in cathepsin,activity (elevated in lysosomes of tumors and inflammatory cells). OsteoSense® 680,a bone turnover imaging agent, was used as a non-tumor imaging control. These,and multiple other PerkinElmer imaging agents, can be used to characterize tumor,biology, and in this set of studies the data shows that two different tumors, HeLa,(cervical cancer) and 4T1 (breast cancer), can differ in their pattern of labeling,intensities for six distinct biological imaging agents. Such an approach is likely to,prove valuable for the full biological characterization of tumors during progression,metastasis, or response to treatment.
Asthma is an inflammatory disease process characterized by reversible airway obstruction and airway hyperresponsiveness. This disease process is driven by activated T lymphocytes and eosinophils that are recruited to the lung upon inhalation of triggering allergens. These cells release inflammatory mediators, activate mast cells and epithelial cells and stimulate mucus secretion, ultimately leading to airway obstruction. The incidence and severity of asthma is increasing worldwide, elevating the need for clinically relevant in vivo animal models that can be used to improve the understanding of asthma biology and the development of effective therapeutics. Here we illustrate the use of PerkinElmer’s FMT® 2500LX Quantitative Pre-clinical Imaging System in combination with ProSense® 680 Fluorescent Pre-clinical Imaging Agent, a near-infrared, protease-activatable agent, for the noninvasive in vivo imaging and quantitation of pulmonary inflammation.
ProSense 750 EX activatable fluorescent imaging agent Protocol
ProSense®750 EX is a protease activatable fluorescent in vivo imaging agent that is activated by key disease associated proteases such as Cathepsin B, L, S and Plasmin. ProSense®750 EX is optically silent in its unactivated state and becomes highly fluorescent following protease-mediated activation.